https://www.selleckchem.com/pr....oducts/rp-102124.htm
Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use off-label is frequently reported. The aim of this study was to describe the broader use and outcomes of a cohort of pediatric patients exposed to eculizumab. A retrospective, cohort analysis was performed on the clinical and biomarker characteristics of eculizumab-exposed patients 25 years of age seen across 21 centers of the Pediatric Nephrology Research Consortium. Patients were included if they received at least one dose of eculizuma
Like
Comment
Share
